Cargando…

Joint Canadian Association of Gastroenterology and Crohn’s Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease

Detalles Bibliográficos
Autores principales:	Moayyedi, Paul, Benchimol, Eric I, Armstrong, David, Yuan, Cathy, Fernandes, Aida, Leontiadis, Grigorios I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985688/ https://www.ncbi.nlm.nih.gov/pubmed/32010877 http://dx.doi.org/10.1093/jcag/gwz035

Ejemplares similares

Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2020)

Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication
por: Leontiadis, Grigorios I, et al.
Publicado: (2018)

COVID-19 Vaccination in Patients With Inflammatory Bowel Disease: Communiqué From the Canadian Association of Gastroenterology
por: Tse, Frances, et al.
Publicado: (2021)

Canadian Association of Gastroenterology (CAG) Position Statement on the Use of Hyoscine-n-butylbromide (Buscopan) During Gastrointestinal Endoscopy
por: Forbes, Nauzer, et al.
Publicado: (2021)

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease
por: Panaccione, Remo, et al.
Publicado: (2019)

COVID-19: Advice from the Canadian Association of Gastroenterology for Endoscopy Facilities, as of March 16, 2020
por: Tse, Frances, et al.
Publicado: (2020)

Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease
por: Mack, David R, et al.
Publicado: (2019)

Canadian Consensus Statements on the Transition of Adolescents and Young Adults with Inflammatory Bowel Disease from Pediatric to Adult Care: A Collaborative Initiative Between the Canadian IBD Transition Network and Crohn’s and Colitis Canada
por: Fu, Nancy, et al.
Publicado: (2022)

American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
por: Abraham, Neena S., et al.
Publicado: (2022)

Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea
por: Sadowski, Daniel C, et al.
Publicado: (2019)

The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn’s and Colitis Canada
por: Benchimol, Eric I, et al.
Publicado: (2019)

Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders
por: Andrews, Christopher N, et al.
Publicado: (2019)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD
por: Bernstein, Charles N, et al.
Publicado: (2021)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications
por: Targownik, Laura E, et al.
Publicado: (2021)

Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology
por: Mularczyk, Aldona, et al.
Publicado: (2014)

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)
por: Moayyedi, Paul, et al.
Publicado: (2019)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life
por: Graff, Lesley A, et al.
Publicado: (2021)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Children and Expectant Mothers With Inflammatory Bowel Disease
por: Benchimol, Eric I, et al.
Publicado: (2021)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary
por: Ellen Kuenzig, M, et al.
Publicado: (2021)

Canadian Association of Gastroenterology Position Statement on the Impact of Simethicone on Endoscope Reprocessing
por: Benmassaoud, Amine, et al.
Publicado: (2018)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy
por: Kaplan, Gilaad G, et al.
Publicado: (2021)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Epidemiology—The Trends of Disease Over Time
por: Coward, Stephanie, et al.
Publicado: (2021)

Gastroenterology Practitioner and Trainee Numbers in Canada 2018: Annual Report From the Canadian Association of Gastroenterology
por: Leddin, Desmond, et al.
Publicado: (2020)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care
por: Jones, Jennifer L, et al.
Publicado: (2021)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations
por: Murthy, Sanjay K, et al.
Publicado: (2021)

European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations
por: Miehlke, Stephan, et al.
Publicado: (2021)

Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
por: Bernasko, Nana, et al.
Publicado: (2021)

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
por: Sood, Ajit, et al.
Publicado: (2020)

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines
por: Jones, Jennifer L, et al.
Publicado: (2021)

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
por: Benchimol, Eric I, et al.
Publicado: (2021)

Canadian Association of Gastroenterology: Strategic Plan 2016–2020
por: McKay, Derek, et al.
Publicado: (2016)

Journal of the Canadian Association of Gastroenterology
por: Marshall, John K
Publicado: (2018)

Position statement of the Polish Society of Gastroenterology and the National Gastroenterology Consultant on vaccination against COVID-19 among patients with inflammatory bowel diseases
por: Eder, Piotr, et al.
Publicado: (2021)

Editorial Review for: Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
por: Hanson, Karen
Publicado: (2021)

Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany
por: Sullivan, Emma, et al.
Publicado: (2017)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring
por: Wasserbauer, Martin, et al.
Publicado: (2022)

COVID-19 and Canadian Gastroenterology Trainees
por: Khan, Rishad, et al.
Publicado: (2020)

Sedation during endoscopic procedures: a Hellenic Society of Gastroenterology Position Statement
por: Viazis, Nikolaos, et al.
Publicado: (2023)

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis
por: Keil, Radan, et al.
Publicado: (2016)

The position statement of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic
por: Łodyga, Michał, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gah3jhrpt93q2esjpnj84b93m6